LiveOne, Inc., a digital media company, engages in the acquisition, distribution, and monetization of live music, Internet radio, podcasting/vodcasting, and music-related streaming and video content. The company operates through three segments: PodcastOne, Slacker, and Media Group. It operates LiveOne, a live music streaming platform; PodcastOne, a podcasting platform; and Slacker, an integrated membership and advertising streaming music service, as well as produces original music-related content. The company also produces, edits, curates, and streams live music events through broadband transmission over the Internet and satellite networks to its users; provides digital Internet radio and music services to users online and through automotive and mobile original equipment manufacturers on a white label basis; and offers ancillary products and services, such as regulatory and post-implementation support services. In addition, it develops, manufactures, and distributes personalized merchandise and gifts through wholesale and direct-to-consumer distribution channels. Further, the company offers LiveOne App, an application that provides access to live events, audio streams, original episodic content, podcasts, vodcasts, video on demand, real-time livestreams, and social sharing of content. The company was formerly known as LiveXLive Media, Inc. and changed its name to LiveOne, Inc. in October 2021. LiveOne, Inc. was incorporated in 2009 and is headquartered in Beverly Hills, California.

LiveOne Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apogee Therapeutics (APGE – Research Report) and Alv...

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Alvotech (ALVO)

LiveOne ( ($LVO) ) has shared an update. LiveOne, Inc. announced its intention to present and distribute its Corporate Presentation to the investme...

LiveOne Announces Corporate Presentation at Conferences

The latest update is out from Alvotech ( ($ALVO) ). On November 24, 2025, Alvotech announced that its biosimilar AVT03, equivalent to Prolia and Xg...

Alvotech’s AVT03 Biosimilar Gains European Approval

In a report released yesterday, Sean McGowan from Roth MKM maintained a Buy rating on LiveOne, with a price target of $13.00. The company’s shares ...

Roth MKM Keeps Their Buy Rating on LiveOne (LVO)

Liveone, Inc. (LVO) has disclosed a new risk, in the Debt & Financing category. Liveone, Inc. faces significant business risks due to the novel and...

Current Quarter	$-0.41	Next Quarter	$-0.39
Current Year	$-1.74	Next Year	$-1.48
QoQ Growth	+4.9%	YoY Growth	+14.9%
3Y EPS CAGR	+29.0%	Target Price	$11.50
Consensus	Buy	Upside	+123.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LVO	$5.15	+0.19%	90.44K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LVO	$5.15	+0.2%	90.44K
3
4
5
6

LVO

LVO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get LiveOne Inc. Data in Excel

Get LiveOne Inc. Data in Excel